News

CECOG is proud to cooperate with the Spanish Breast Cancer Research Group (GEICAM) on the trial “Phase III study of exemestane plus palbociclib (PD-0332991) versus chemotherapy in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) with resistance to non-steroidal aromatase inhibitors.”

Colorectal Cancer

CECOG/DREAM (MO18420)

Phase III study of an optimized chomotherapy + Avastin ® Strategy + Tarceva ® in metastatic colorectal cancer. Optimox 3-Tarceva ® Study. C04-2.

Status: successfully closed after recruitment

CECOG/CORE.1.2.001

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX 6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer.

Status: successfully closed after recruitment

CECOG/CORE.1.2.002

A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + weekly Cetuximab versus FOLFOX4 + bi-weekly Cetuximab as first-line therapy in patients with metastatic colorectal cancer.

Status: recruitment finalized

Pancreatic Cancer

CECOG/PAN 1.3.001, SAKK 44/00

Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer.
A randomized phase III trial. SAKK 44/00

Status: successfully closed after recruitment

Breast Cancer

CECOG/BC.1.2.001

A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic disease.

Status: recruitment finalized

CECOG/BC.1.3.005

A randomized phase III trial of Paclitaxel plus Bevacizumab versus Capecitabine plus Bevacizumab for the first line treatment of HER2-negative locally recurrent or metastatic breast cancer.

Status: recruitment finalized

» Final Protocol

CECOG/BREAST.2.2.005

A Randomized Phase II Study of Dose-Dense Fluorouracil plus Epirubicin75 plus Cyclophosphamide (FEC75) and Fluorouracil plus Epirubicin90 plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer

Status: successfully closed after recruitment

CECOG/BC.1.3.002

A Randomized Phase III Study Comparing Concomitant Docetaxel plus Gemcitabine to Sequential Therapy of Docetaxel followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients.

Status: successfully closed after recruitment

CECOG/GBG

Eine multizentrische Studie der Phase III zum Vergleich von Capecitabin alleine oder in Kombination mit Trastuzumab bei Patientinnen mit HER2 positiver metastasierter Brustkrebserkrankung und Progression nach vorheriger Behandlung mit Trastuzumab (Behandlung nach Progression).

A multicenter randomized phase III study to compare capecitabine alone versus capecitabine with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with taxanes and trastuzumab (Treatment Beyond Progression, TBP).

Status: successfully closed after recruitment

Phase III Study of Gemcitabine/Epirubicin/Paclitaxel Combination versus Standard 5-Fluorouracil/Epirubicin/Cyclophosphamide Combination as First Line Chemotherapy in Metastatic Breast Cancer: GET versus FEC (CECOG-BM1)

Status: successfully closed after recruitment

Published in: Proc. Am. Soc. Clin. Oncol. 25:26, 2003 and J. Clin. Oncol. 2005 Mar 1; 23(7):1401-8

CECOG/BC.1.3.006 – GEICAM/PEARL Trial

Phase III study of exemestane plus palbociclib (PD-0332991) versus chemotherapy in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) with resistance to non-steroidal aromatase inhibitors.

CECOG cooperates with the Spanish Breast Cancer Research Group (GEICAM) on this trial.

Status: Recruiting

Esophago-Gastric Cancer

CECOG/ESGAS 1.2.001

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally recurrent esophagogastric cancer previously untreated with chemotherapy for advanced disease

Status: successfully closed after recruitment

CECOG/ESGAS 1.2.002

A Phase II Study of Irinotecan, mitomycin C and capecitabine as second line chemotherapy for patients with metastatic or locally recurrent esophago-gastric cancer previously treated with chemotherapy for advanced disease.

Status: successfully closed after recruitment

Non Small Cell Lung Cancer

CECOG/NSCLC.1.1.001

Dacomitinib (PF-00299804) in combination with pemetrexed for patients with advanced non squamous non-small cell lung cancer (NSCLC): a phase I trial evaluating the MTD and safety of pemetrexed + dacomitinib treatment in patients with stage IV NSCLC.

Status: recruitment ongoing

CECOG collaborates in the EMPHASIS-lung ETOP 3-12 Trial

A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by VeriStrag Good vs VeriStrat Poor” – EMPHASIS-lung ETOP 3-12 with 4 sites in Israel and 2 sites in Austria.

Status: closed

CECOG participated in the ALIMTA – H3E-MC-JMEN Trial

A phase III, double-blinded, placebo-controlled study of Pemetrexed plus best supportive care vs. best supportive care as maintenance therapy immediately following induction treatment for advanced Non-Small Cell Lung Cancer.

Status: successfully closed after recruitment

CECOG/NSCLC.3.2.002

A Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo- Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer

Status: successfully closed after recruitment

Gemtax III

Phase III comparing first line combination therapy versus sequential chemotherapy with Docetaxel and Gemcitabine in advanced Non Small Cell Lung Cancer (NSCLC)
A cooperation with the Thoraxklinik Heidelberg, Germany.

Status: successfully closed after recruitment

CECOG/NSCLC.2.2.001

An open, randomized, multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the adjuvant treatment of Non-Small Cell Lung Cancer (NSCLC)
Stage I-II

Status: successfully closed after recruitment

Gemcitabine and Cisplatin With and Without Subsequent Maintenance Therapy with Single Agent Gemcitabine in Stage IV Non-small Cell Lung Cancer. A Randomized, Multicentric Study (CECOG-NSCLC1)

Status: successfully closed after recruitment

Published in : Lung Cancer 41, Suppl. 2:O-88, 203 and Lung Cancer 2006 May; 52(2):155-63

CECOG/SPLENDOUR Trial

CECOG is proud to cooperate with the European Thoracic Oncology Platform (ETOP) on the trial “A randomized, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC”.

Trial News: The SPLENDOUR trial included the first patient

Gastrointestinal Stromal Tumours

CECOG/GIST 1.2.001

Open-label Trial of Glivec in Patients with Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing c-kit

Status: successfully closed after recruitment

GIST 1.2.002 Molecular Substudy

Molecular mechanisms associated with response/resistance to Glivec in patients with unresectable or metastatic malignant gastrointestinal stromal tumur expressing c-kit.

Status: successfully closed after recruitment

Prostate Cancer

CECOG/PROSTATE 1.2.001

A randomised open-label (ZOMETA® + hormonal ablation vs. hormonal ablation alone) multicenter prospective clinical study to show the efficacy of intravenous ZOMETA® (zoledronic acid) 4 mg for prevention of bone metastases in hormone-naïve high risk patients with locally advanced prostate cancer.

Status: successfully closed after recruitment

Prof. Zielinski on Clinical Trials

CECOG Contact Information

Please feel free to contact us if you have any questions.

  • by phone: +43/1/409 77 25

  • christiane.thallinger@cancer-center.cc

  • or fill in the form on contact page